Buffalo Neuroimaging Analysis Center | Strategic Alliance Partners
BNAC is a leading neuroimaging research center extending the boundaries of knowledge about neurological disease and disorders through innovative research techniques and advanced neuroimaging bioinformatics. BNAC scientists perform pre-clinical and clinical trials as well as patient-centered, investigator-initiated studies with specialization in MS, Parkinson’s Disease, stroke.
Led since 2003 by its Director Robert Zivadinov, MD, Ph.D., the Center is part of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, State University of New York.
Latest from Buffalo Neuroimaging Analysis Center
Ocrelizumab’s Impact on Humoral Response to EBV: Robert Zivadinov, MD, PhD
November 1st 2022The director of the Buffalo Neuroimaging Analysis Center provided context on a new study exploring ocrezliumab’s (Ocrevus; Genentech) effect on leptomeningeal inflammation and humoral response to EBV. [WATCH TIME: 5 minutes]
Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple Sclerosis
April 25th 2022Robert Zivadinov, MD, PhD, discusses the design of a novel comparative study assessing the effect of siponimod (Mayzent; Novartis) and ocrelizumab (Ocrevus; Genentech) on microglia and astrocytes in patients with SPMS.
Next Steps in Understanding Cognitive Decline in Aging MS: Dejan Jakimovski, MD, PhD
January 11th 2022The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]
MS Disease-Modifying Therapy Discontinuation Associated With Disability Progression
January 5th 2022DMT discontinuation resulted with new disability worsening and/or progression in previously stable patients with relapsing-remitting MS and particularly in patients with previously stable secondary progressive MS.
Understanding Cognitive Decline Based on Multiple Sclerosis Phenotype: Dejan Jakimovski, MD, PhD
January 4th 2022The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 3 minutes]
Realistic Outlook of Integrating Positive Remyelination Strategies in Clinical Trials
November 10th 2021Robert Zivadinov, MD, PhD, provides thoughts on hurdles of conducting clinical trials that incorporate imaging techniques sensitive and specific to myelin for patients with multiple sclerosis.
Future Direction of AI, Neuroimaging Research: Michael Dwyer, PhD
September 22nd 2021The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]
Applying Artificial Intelligence and Neuroimaging Into Clinical Care: Michael Dwyer, PhD
September 16th 2021The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided a realistic perspective of when and how AI will be incorporated into the wider medical system.
Atrophied Lesion Volume as a Biomarker of Disability in Progressive Multiple Sclerosis
June 29th 2021Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.
